Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895”

Detalles Bibliográficos
Autores principales: Rayson, Daniel, Gandhi, Sonal, Joy, Anil A., Brezden-Masley, Christine, Gelmon, Karen A., Sehdev, Sandeep, Cescon, David, Chia, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Reply
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217302/
https://www.ncbi.nlm.nih.gov/pubmed/37232839
http://dx.doi.org/10.3390/curroncol30050381
Descripción
Sumario:

Ejemplares similares